Is the antihypertensive activity of Hibiscus sabdariffa affected by factors such as origin of the plant and time of decoction? Implications for clinical practice

Q: What is the clinical evidence from this study?

Population: Hypertension (n=369). Intervention: Hibiscus sabdariffa decoction vs. Different batches and decoction times (10 vs 20 minutes). Primary outcome: Blood pressure reduction correlation with total anthocyanins and hibiscus acid content across different batches.

Q: What does this research mean for the field?

The batch origin of Hibiscus sabdariffa does not significantly alter its antihypertensive efficacy, with hibiscus acid acting as the primary active principle despite variations in anthocyanin content. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Anne-Laure Cavin; Laurence Marcourt; Fabien Félix; Nicolas Low‐Ders; Thomas Louis; Robert Drummond; Renata Campos Nogueira; Marwah Al-Anbaki; Emerson Ferreira Queiroz; Jean‐Luc Wolfender; Bertrand Graz

doi:10.1038/s41371-026-01233-7

October 6, 2026Journal of Human HypertensionOpen Access

Is the antihypertensive activity of Hibiscus sabdariffa affected by factors such as origin of the plant and time of decoction? Implications for clinical practice

View Full Paper

Ask AI

Bookmark

Share

Key result

Consistent hibiscus acid levels drive steady BP reductions despite ~4-fold batch variations in anthocyanins.

n=369

Why the study?

The influence of Hibiscus sabdariffa plant origin and decoction time on its antihypertensive activity and active substance yield was unclear, affecting clinical use recommendations.

Does Hibiscus sabdariffa decoction reduce blood pressure in patients with hypertension regardless of plant origin and decoction time?

Key Points

To assess whether plant origin and decoction duration alter the extraction of active compounds and blood pressure-lowering efficacy of Hibiscus sabdariffa.
Analyzed individual blood pressure progress across three multicenter clinical trials in Jordan (single-arm pilot, n=29), Senegal (five-arm randomized trial, n=31 in hibiscus decoction arm), and Iraq (two-arm randomized trial, n=76 in hibiscus decoction arm) after 3-4 weeks of treatment.
Quantified total anthocyanins and hibiscus acid concentrations across batches originating from Nigeria and Senegal using 10-minute and 20-minute decoctions.
Hibiscus acid yield remained stable across batches at 19% to 25% of dry extract, whereas total anthocyanins varied up to 4.5-fold between trials and increased with a 20-minute compared to a 10-minute decoction.
Systolic blood pressure decreased from 149.1 ± 18.6 to 133.9 ± 18.1 mmHg in Jordan, from 159.1 ± 15.5 to 140.6 ± 18.6 mmHg in Senegal, and from 151.6 ± 11.7 to 130.6 ± 9.8 mmHg in Iraq.
Diastolic blood pressure decreased from 98.3 ± 12.5 to 92.4 ± 11.6 mmHg in Jordan, from 97.4 ± 12.5 to 89.9 ± 8.6 mmHg in Senegal, and from 93.9 ± 8.8 to 84.4 ± 7.8 mmHg in Iraq.

Structured PICO

Does Hibiscus sabdariffa decoction reduce blood pressure in patients with hypertension regardless of plant origin and decoction time?

P

Population

369 adults with hypertension pooled from three clinical trials, evaluated after 3 to 4 weeks of consuming Hibiscus sabdariffa decoction.

I

Intervention

Hibiscus sabdariffa decoction (tea) administered on a dose-response adaptive scheme, starting at 10 g of dried calyx boiled in 0.5 L of water for 15-20 minutes daily, up to 20 g/day for 3 to 4 weeks.

C

Comparator

Depending on the original trial, patients received either no control, captopril, or continued with their usual treatment.

O

Outcome

Reduction in systolic and diastolic blood pressure after 3 to 4 weeks of treatment.surrogate

Hibiscus sabdariffa tea exhibits reliable antihypertensive activity driven primarily by its consistent hibiscus acid content, regardless of natural variation in total anthocyanins linked to plant origin.

Limitations

Comparison was made on only 3 batches of the Hibiscus sabdariffa decoction
Pooled data from 3 small clinical studies with highly heterogeneous populations and designs
Differences in baseline characteristics, compliance, current medications, daily dietary intake, and physical activity status
Variations in adaptative dose regimens and use of completer analysis
Lack of formal hypothesis testing due to study differences
Differences between contributing studies in design, sample size, confounding factors, and populations.
Groups were defined according to adaptive dosing regimens rather than original randomized groups.
Lack of formal hypothesis testing or appropriate meta-analytic techniques for between-group differences.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Hibiscus acid may drive consistent BP reductions with Hibiscus sabdariffa; hypothesis-generating for targeted standardization in future trials.

Abstract

Hibiscus sabdariffa is effective against hypertension in clinical trials, with a dose-response effect, making it an important, accessible and sustainable treatment. The aim of the present work was to clarify the influence of origin of Hibiscus on clinical effect and decoction time on the yield of active substances, in order to issue recommendations for use. This study reviewed blood pressure progress in three clinical trials after 3-4 weeks of Hibiscus tea consumption, with batches analyzed for total anthocyanins (TA) and hibiscus acid (HA), the 2 known active substances, with two different decoction times (10 vs 20 min). HA levels appeared consistent across batches for a given decoction time, whereas TA levels varied up to 4-fold. Despite this variation, clinical outcomes remained similar. Quantities of TA extracted increased with a longer decoction time. These results suggest that the batch of Hibiscus does not significantly influence its antihypertensive activity, and that HA is a main active principle. Thus, a future perspective of this work could be the development of a more available method, other than NMR, for the characterization of the HA content. Clinical practice should involve adjusting Hibiscus dosage based on individual BP response. Starting treatment with, instead of 10 g, 2.5 g/day and adjusting as needed is recommended, and a 20 min decoction remains advisable. HS decoctions can be recommended for broad BP control thanks to their safety and effectiveness.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cavin et al. (2026) studied Hypertension (n=369). Hibiscus sabdariffa decoction vs. Different batches and decoction times (10 vs 20 minutes) was evaluated on Blood pressure reduction correlation with total anthocyanins and hibiscus acid content across different batches. Despite up to a 4-fold variation in total anthocyanin levels across different batches of Hibiscus sabdariffa, hibiscus acid levels and clinical blood pressure reductions remained consistent, suggesting hibiscus acid is a main active principle.

synapsesocial.com/papers/6ac74632947fe0d7c56432c7 https://doi.org/10.1038/s41371-026-01233-7

View Full Paper

Ask AI

Bookmark

Share

Is the antihypertensive activity of Hibiscus sabdariffa affected by factors such as origin of the plant and time of decoction? Implications for clinical practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Is the antihypertensive activity of Hibiscus sabdariffa affected by factors such as origin of the plant and time of decoction? Implications for clinical practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading